Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment

Author: Benzinga Newsdesk | March 04, 2024 08:05am

Posted In: CCCC MKKGY